The emergence and spread of antimicrobial-resistant bacterial, viral, and fungal pathogens for which diminishing treatment options are available is of major global concern. New viral respiratory tract infections with epidemic potential, such as severe acute respiratory syndrome, swine-origin infl uenza A H1N1, and Middle East respiratory syndrome coronavirus infection, require development of new antiviral agents. The substantial rise in the global numbers of patients with respiratory tract infections caused by pan-antibiotic-resistant Gram-positive and Gram-negative bacteria, multidrug-resistant Mycobacterium tuberculosis, and multiazole-resistant fungi has focused attention on investments into development of new drugs and treatment regimens. Successful treatment outcomes for patients with respiratory tract infections across all health-care settings will necessitate rapid, precise diagnosis and more eff ective and pathogenspecifi c therapies. This Series paper describes the development and use of new antimicrobial agents and immunebased and host-directed therapies for a range of conventional and emerging viral, bacterial, and fungal causes of respiratory tract infections.
Introduction
The emergence of diffi cult-to-treat known and novel bacterial, viral, and fungal respiratory tract pathogens with epidemic potential is of major global concern. Treatment options are limited by increasing antimicrobialdrug resistance. However, new viral infections causing severe respiratory tract disease with pandemic potential have focused global attention. 1 A substantial rise in the number of patients with multidrug-resistant pulmonary tuberculosis 2 and pan-drug-resistant bacteria 3 has been noted. Increasing use of immunosuppressive agents, broad-spectrum antibiotics, and anticancer agents, coupled with resistance to azoles, has led to an increase in the number of invasive pulmonary fungal infections 4 with resultant high morbidity and mortality. Successful treatment outcomes for patients with respiratory tract infections across all health-care settings require appropriate, eff ective, and pathogen-specifi c drug or alternative treatments. We describe a range of conventional and emerging viral, bacterial, and fungal causes of respiratory tract infections for which new antimicrobial drugs and immune-based and host-directed therapies are being developed and studied.
Viral respiratory tract infections
The outbreak of severe acute respiratory syndrome coronavirus (SARS-CoV), 5 re-emergence of avian infl uenza A H5N1, 6 global circulation of oseltamivirresistant seasonal infl uenza A H1N1, 7 and subsequent emergence of the pandemic infl uenza A H1N1 strain pdm09 virus (which continues to circulate), 8 have shown the potential limitations of current antiviral treatments for severe respiratory viral infections. Epidemic waves of avian infl uenza A H7N9, 9 sporadic cases of avian infl uenza A H10N8, 10 the ongoing outbreak of Middle East respiratory syndrome coronavirus (MERS-CoV) infection, and the burden of common respiratory viruses 11 -such as seasonal infl uenza, respiratory syncytial virus, rhinoviruses, and adenoviruses-show that the development of more eff ective therapies to reduce morbidity and mortality is urgently needed. Research is focused on the repurposing of available antiviral drugs for generic or specifi c use and for • Respiratory tract infections are among the top two causes of morbidity and mortality worldwide. Antimicrobial-resistant species of bacteria, viruses, and fungi continue to emerge globally. • A substantial rise in the numbers of cases of multidrug-resistant bacteria, azoleresistant fungi, and oseltamivir-resistant infl uenza A H1N1 causing respiratory tract infections has been identifi ed, showing the potential limitations of current antibiotic, antiviral, and antifungal treatments for severe respiratory tract infections. • Epidemic waves of avian infl uenza A H7N9 virus, sporadic cases of avian infl uenza A H10N8, and the ongoing outbreak of Middle East respiratory syndrome coronavirus infection show an urgent need for the development of more eff ective antivirals. • Research is focused on repurposing available antiviral drugs for generic or specifi c use, or combination use with other adjunct interventions such as immunomodulators and host-directed therapies. • Only one class of eff ective antiviral agents are approved for prevention and treatment of infl uenza in most countries: neuraminidase inhibitors (oseltamivir, peramivir, zanamivir, and laninamivir). • Antibiotic treatment options are limited for pan-antibiotic resistant Gram-negative bacteria, and new antibacterial antibiotic pipeline remains thin. • Increased investments into development of new antibacterial drugs and other antibacterial innovations and for more prudent use of existing antibiotics are required worldwide. • Development of new therapeutic options needs to be coupled to international regulations on the use and prescription of antimicrobial drugs. 
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Infl uenza viruses Drugs
Two classes of antiviral drugs are approved for the prevention and treatment of infl uenza in most countries: M2 inhibitors (amantadine and rimantadine) and neuraminidase inhibitors (oseltamivir, peramivir, zanamivir, and laninamivir; table 1). In general, antiviral treatment is indicated as early as possible for any patient with confi rmed or suspected infl uenza who has severe, complicated, or progressive illness or is admitted to hospital, and in outpatients at higher risk of infl uenza complications. 12, 13 Time to treatment after onset of symptoms, illness severity, and extent of viral replication are key variables with respect to response. Starting of treatment should not be delayed for diagnostic testing. M2 inhibitors-also known as adamantanes-are ineff ective against infl uenza B viruses and recently circulating infl uenza A H3N2 and 2009 pandemic infl uenza A H1N1 viruses, which are resistant because of an S31N mutation in the M2 ion channel. 12 However, a proportion of avian infl uenza A H5N1 strains will be susceptible, 14 and the combined use of an adamantane and a neuraminidase inhibitor improves antiviral activity for susceptible isolates. 15 Two neuraminidase inhibitors are approved for use in most countries: oseltamivir and zanamivir. Laninamivir is approved for use in Japan only, and peramivir in China, Japan, and South Korea. Several observational studies have shown that when adults admitted to hospital with severe infl uenza are given oseltamivir, mortality falls and clinical outcomes improve, especially when treatment is initiated within 2 days of the onset of symptoms (but positive eff ects are noted when it is begun as late as 4-5 days after onset). 12, 13, 16, 17 Oseltamivir reduces mortality in infl uenza A H5N1 infection when given before the onset of respiratory failure, 18 and might be benefi cial when started as late as 6-8 days after symptom onset. 19 In patients admitted to hospital with severe infl uenza A H7N9 infection, reduction of viral load after treatment with oseltamivir correlated with improved outcome, whereas the emergence of virus resistant to neuraminidase inhibitors that harbours an Arg292Lys substitution is associated with poor outcomes and poor response to oseltamivir and peramivir. 20 The standard duration of oseltamivir treatment is 5 days; longer treatment is recommended for critically ill patients with respiratory failure, who often have prolonged viral replication in the lower respiratory tract despite treatment. 13 Whether increased doses provide greater antiviral eff ects in such patients is under investigation. A randomised controlled trial 21 of patients in hospital (76% of whom were children) showed no virological or clinical advantages when a double dose of oseltamivir was given rather than a standard dose. No additional benefi t was noted with high-dose oseltamivir in adults admitted with infl uenza A, although a faster virological response was noted in those with infl uenza B. 22 However, in a randomised controlled trial 23 of 18 critically ill patients with 2009 pandemic infl uenza A H1N1, a triple-dose oseltamivir regimen was associated with signifi cantly higher proportions of viral clearance at 5 days than was standard therapy (78% vs 11%; p=0·015). 23 Studies of intravenous neuraminidase inhibitors that are underway should provide further data on the value of high-dose therapy.
Zanamivir and laninamivir have generally similar profi les of susceptibility. For example, the His275Tyr mutation confers high-level resistance to oseltamivir carboxylate and reduced susceptibility to peramivir in N1containing viruses but does not substantially diminish susceptibility to zanamivir and laninamivir. 30 Inhaled zanamivir has not been studied in detail in severely ill patients or those admitted to hospital, in whom eff ective delivery to sites of viral replication and tolerability could be an issue. By contrast, intravenous zanamivir has been used widely on a compassionate basis since the 2009 H1N1 pandemic, particularly for late treatment of critically ill adults with 2009 pandemic infl uenza A H1N1 virus infection and those with suspected or proven oseltamivir resistance. 31 One trial 32 has shown no drug-related trends in safety measures, and a subset of 93 patients positive at baseline for infl uenza showed a median decrease in nasopharyngeal viral RNA load of 1·42 log 10 copies per mL after 2 days of treatment. A phase 3 trial in patients who have been admitted to hospital is underway (NCT01014988). A phase 2 randomised controlled trial of inhaled laninamivir in uncomplicated infl uenza failed to show superiority in illness alleviation (primary endpoint) compared with placebo. The trial, involving 639 patients, tested 40 mg and 80 mg doses of the inhaled drug. The median time to alleviate fl u symptoms was 102·3 h for the 40 mg dose and 103·2 h for the 80 mg dose, compared with 104·1 h for the placebo (NCT01793883).
DAS181 has host-directed receptor-destroying action, which is inhibitory for parainfl uenza and infl uenza viruses, including those resistant to amino adamantanes and neuraminidase inhibitors. 15 When delivered topically, it is eff ective in animal models of lethal infl uenza caused by the H5N1 and H7N9 viruses, including the neuraminidase-inhibitor-resistant Arg292Lys -containing variant. 35 In a phase 2 randomised controlled trial, 36 inhaled DAS181 reduced pharyngeal viral replication in uncomplicated infl uenza but did not reduce nasal viral loads or improve clinical outcomes. Case reports 37 suggest that inhaled or nebulised DAS181 might be eff ective in immunocompromised hosts with severe parainfl uenza lung disease.
Favipiravir (T-705; 6-fl uoro-3-hydroxy-2-pyrazinecarboxamide) is active against infl uenza A, B, and C viruses, including strains resistant to approved antivirals, and a broad range of other RNA viruses when given at Series somewhat higher concentrations. 38 Combinations of favipiravir and neuraminidase inhibitors have additive and synergistic eff ects in preclinical models, 39 but clinical trials have been restricted to uncomplicated infl uenza so far. These clinical trials (combination amantadine, ribavirin, and oseltamivir vs oseltamivir mono therapy [NCT01227969], nitazoxanide vs oseltamivir vs combination vs placebo [NCT01610245], favipiravir vs placebo randomised controlled trial in outpatients [NCT02008344, NCT2026349]), which have not been published, suggest that favipiravir has antiviral eff ects similar to those of oseltamivir. 40 A randomised controlled trial 41 showed that favipiravir shortened the time to alleviation of infl uenza symptoms by about 15 hours compared with placebo, and further studies are underway.
Nitazoxanide is an oral antiparasitic drug with immunomodulatory eff ects, including upregulation of interferon and various interferon-inducible genes and a specifi c infl uenza-inhibitory eff ect related to blockade of haemagglutinin maturation. 42 Nitazoxanide inhibits infl uenza replication in vitro 43 and in a phase 2 randomised controlled trial 44 had signifi cant antiviral eff ects (1·0 log 10 reduction in nasal viral loads) and resulted in a signifi cantly faster time to alleviation of illness (roughly 20 h diff erence in medians from placebo) in uncomplicated infl uenza. 44 A placebocontrolled randomised trial of nitazoxanide versus oseltamivir-and the com bination thereof-in uncomplicated infl uenza and a hospital-based study of its use in severe respiratory illness are in progress (NCT01610245).
Immune-based treatments for infl uenza
Non-randomly assigned studies and case reports suggest that convalescent plasma with neutralising antibodies is a useful add-on therapy for patients with SARS and severe infl uenza pneumonia, including that caused by infl uenza A H5N1. 45 A recently published systematic review of available SARS and infl uenza treatment studies employing convalescent plasma or serum found a signifi cant overall mortality benefi t. 46 A prospective observational study 47 showed lower crude mortality and faster nasopharyngeal viral clearance in plasma-treated patients who were admitted with severe 2009 pandemic infl uenza A H1N1 infection, whereas in a randomised controlled trial 48 a reduction in mortality was reported in severe illness when hyperimmune globulin was given within 5 days of the onset of symptoms (table 2) . Heterosubtypic haemagglutinin stem-neutralising antibodies, which are highly eff ective in animals, 49 are entering clinical evaluation in human beings.
Combinations of antivirals
The combination of antivirals with diff erent mechanisms of actions (eg, a neuraminidase inhibitor with a polymerase inhibitor such as favipiravir, 38 a broad-spectrum antihaemagglutinin-neutralising antibody, 49 Oseltamivir and corticosteroids (19) More rapid improvement in partial pressure of oxygen, fraction of inspired oxygen, and sequential organ failure assessment scores; shorter ventilator use (median 7 days vs 15 days, p=0·03); and faster viral clearance in the sirolimus than in the control group RCT=randomised controlled trial. Series emergence of resistance, and perhaps spare doses has been explored in preclinical studies. 15, 50 However, few combination studies have been focused on eff ectiveness (table 2) . By contrast with combinations of drugs with diff ering mechanisms of action, combination of optimum doses of drugs with similar mechanisms of action (eg, dual neuraminidase inhibitors) does not enhance 51 antiviral activity and can sometimes result in antagonism. 52.53 A triple combination of antiviral drugs consisting of amantadine, ribavirin, and oseltamivir showed synergistic in-vitro activity against infl uenza A viruses that were susceptible to all three drugs and also those resistant to the amantadine or oseltamivir at baseline, including 2009 pandemic infl uenza A H1N1 virus. 51 In a retrospective study 53 of critically ill adults, mortality rates did not diff er between those who received a triple combination of antiviral drugs and those receiving oseltamivir only, and a randomised controlled trial sponsored by the National Institute of Allergy and Infectious Diseases in higher-risk outpatients is underway (NCT01227969).
Antivirals combined with host-directed therapies
Host-directed therapies aim to reduce the damaging consequences of the host immune response to the pathogen. Combinations of antivirals with host-directed therapies such as the immunomodulator sirolimus, an mTOR inhibitor that blocks host pathways needed for viral replication (table 2) , 54 might also enhance antiviral activity.
Other host-directed therapies inhibiting cellular targets needed for effi cient viral replication (eg, the Raf-MEK-ERK mitogenic kinase cascade and the IKK-NF-κB module) might provide future options for clinical testing. 15 The role of adjunctive immunomodulatory therapies in severe infl uenza and other respiratory viral infections remains uncertain. Several observational studies show that systemic corticosteroids given for 2009 pandemic infl uenza A H1N1-associated viral pneumonia increased the risk of mortality and morbidity (eg, secondary infections), especially when there was a delay in initiation, or absence of, eff ective antiviral therapy. 45 Their use might delay viral clearance and increase the risk of the emergence of resistance 20 and fungal infections. 45 Other potential adjunctive therapies for infl uenza include intravenous immunoglobulin, N-acetylcysteine, statins, macrolides, peroxisome proliferator-activated receptor agonists, celecoxib, mesalazine, plasmapheresis, and haemo perfusion. 45 Chloroquine was eff ective against infl uenza A H5N1 infection in one animal model 55 but was ineff ective in other animal models and one human randomised controlled trial. 56, 57 
MERS-CoV infection
Interferons MERS-CoV infection can cause severe respiratory disease, and has higher mortality in those with medical comorbidities. Although empirical treatment with a range of antivirals has been tried for severe respiratory tract infections caused by MERS-CoV and SARS-CoV, no regimens have been rigorously assessed in clinical trials (panel). 58, 59 MERS-CoV elicits attenuated innate immune responses with delayed proinfl ammatory cytokine induction in cell culture and in vivo. 60, 61 It is also readily inhibited by type 1 interferons (interferon alfa and especially interferon beta), suggesting a potential therapeutic use for interferons. Early pegylated interferon alfa therapy was eff ective in a SARS primate model, and treatment with interferon-alfa-consensus-1 plus systemic corticosteroids was associated with improved oxygen saturation and more rapid resolution of radiographic lung opacities than were systemic corticosteroids alone in an uncontrolled study of patients with SARS patients. 62 Further studies of interferons in MERS-CoV seem warranted.
Antiviral drugs
Ribavirin was used extensively in patients with SARS without any benefi cial eff ects and was complicated by haemolytic anaemia and metabolic disturbances in many cases. 58, 59 A combination of interferon alfa 2b and ribavirin reduced lung injury and moderately decreased viral replication (<1·0 log 10 reduction in lung titres) when given to rhesus macaques within 8 h of inoculation with MERS-CoV. 63 The treatment combination was given to several severely ill patients with MERS, but the infections proved fatal, probably because of late administration in the advanced stage of the disease. 64, 65 Ribavirin has in-vitro inhibitory eff ects against MERS-CoV. 66, 67 The inhibitory concentrations of ribavirin are very high for MERS-CoV and exceed those that can be achieved with usual dosing regimens, except possibly peak concentrations after high intravenous doses. 
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The use of protease inhibitors with lopinavir and ritonavir as initial therapy in SARS was associated with signifi cantly less death (2·3% vs 15·6%, p<0·05) and intubation (0% vs 11·0%, p<0·05) than was use of ribavirin alone in a matched historical cohort (n=44 for lopinavir and ritonavir as intial treatment vs n=634 for the matched historical cohort). 68 However, one study reported that nelfi navir and lopinavir have high 50% eff ective inhibitory concentrations (EC 50 ) against MERS-CoV in vitro, 66 whereas another found inhibition with lopinavir at clinically achievable concentrations. 69
Immunomodulatory and immune-based therapies
Several drugs have shown inhibitory eff ects against MERS-CoV in cell cultures, including interferons, ciclosporin, and mycophenolic acid. 66, 67, 69 Mycophenolic acid was inhibitory at clinically achievable concentrations, and the combination of mycophenolic acid and interferon β1b lowered the EC 50 of each drug by one-to-three times. 66 Dipeptidyl peptidase 4 (DPP4), also known as CD26, is a functional receptor for MERS-CoV, and an anti-CD26 polyclonal antibody showed in-vitro inhibitory eff ects on MERS-CoV. 70 By contrast, inhibitors of the enzymatic action of DPP4 (eg, gliptins) did not inhibit viral replication.
Timely administration of neutralising antibodies could have a high likelihood of therapeutic success. 46 Treatment with convalescent plasma (from patients who have recovered from SARS-CoV infection) containing high levels of neutralising antibody within 2 weeks of illness onset resulted in a higher proportion of discharges at day 22 than did treatment more than 14 days after onset (58% vs 16%, p<0.001). 71 Some patients who survived MERS-CoV infection had high concentrations of neutralising antibody, 72, 73 and convalescent plasma, if available, might provide a good treatment option for other severe cases.
Systemic corticosteroids have been used empirically frequently in SARS 58, 59 and MERS-CoV 64,65 infections to dampen immunopathological host responses. However, survival benefi t is unclear, 59,64,65 and a randomised controlled trial 74 done in Hong Kong showed that systemic corticosteroids could delay viral clearance in SARS. A retrospective analysis 75 showed worse outcomes when systemic corticosteroids were given in SARS. Consequently, their use should be avoided unless a carefully controlled prospective study is done to test their eff ectiveness when combined with an antiviral. Several observational studies have shown that systemic corticosteroids given for 2009 pandemic infl uenza A H1N1-asssociated viral pneumonia or acute respiratory distress syndrome increased the risk of mortality and morbidity (eg, secondary bacterial or fungal infections), especially if there is delay or lack of eff ective antiviral therapy. 45 Use of systemic corticosteroids has probably contributed to delayed viral clearance and emergence of antiviral resistance in patients with severe infl uenza A H7N9 infection requiring extracorporeal membrane oxy genation. 20 Infl uenza increases the risk of invasive aspergillosis, especially among immunocompromised patients, and this is often a silent infection in the early stages, 76 so direct surveillance with aspergillus antigen and PCR testing on respiratory secretions is advisable. Patients treated for fungal infections will have to undergo antifungal therapeutic drug monitoring. 77 Data are insuffi cient to support routine use of any of the immune therapies. Better animal data and careful systematic clinical studies, including serial virological measurements of priority treatments such as convalescent plasma and interferons (and randomised controlled trials if case numbers are suffi cient), are needed. Currently, clinical management of patients with severe respiratory tract infections due to MERS-CoV largely relies on meticulous intensive care supportive treatment and prevention of complications.
Host-directed therapy for viral infections T-cell therapy
Research done in patients with haemopoietic stem-cell transplants shows that adoptive transfer of antigenspecifi c T cells can restore protective immunity and prevent or reverse disease due to opportunist viral infections such as cytomegalovirus. 78 In transplant recipients, transfer of donor-derived T cells can result in resolution of infection through expansion of virusspecifi c T cells, with associated clinical improvement. 79 Transfer of donor T cells is associated with the risk of severe acute graft-versus-host disease, and thus most T-cell therapies have been done in patients who have low lymphocyte counts. Lymphopenia enables only a very low number of T cells to be transferred, which then proliferate in lymphopenic hosts, most likely as a result of the interleukins 7 and 15 if the patient does not receive immunosuppressive treatment during T-cell therapy. 80 T-cell therapy targeting cytomegalovirus strains resistant to drug treatment is clinically relevant in lung transplant recipients. 81 T-cell expansion requires time to induce clinical regression of viral infection. Several other approaches might be applicable in situations that necessitate fast clinical action-eg, use of synthetic MHC antigens loaded with the relevant peptide from the pathogen of interest (so-called tetramer or multimer MHC-peptide complexes), which engage pathogenspecifi c lymphocytes expressing the pathogen-specifi c T-cell receptors. Pathogen-specifi c T cells can be isolated through use of soluble MHC-peptide complexes, and can immediately be transferred into patients for salvage treatments for viral infections. 82 T-cell expansion can also be achieved with several stimuli targeting several infectious pathogens. 83 Expansion of T cells targeting several antigens of cytomegalovirus, Epstein-Barr virus, and adenovirus provides broad antiviral specifi city after stem-cell transplantation. 84 An alternative approach to Series become independent of ex-vivo expansion of T cells is the identifi cation of T-cell receptors that would recognise viral infected cells that could be transferred into recipient eff ector cells. 85 T cells can also be engineered to produce an antiviral RNA that would block viral infection. 86 
Antisense molecules
Synthetic antisense molecules, such as phosphorodiamidate morpholino oligomers, are structurally similar to RNA but the phosphorodiester linkage is replaced with a neutral phosphorodiamidate linkage and the ribose ring with a six-membered morpho lino ring. 87 They change gene expression by inhibiting translation, disrupting RNA secondary structure, and interfering with pre-mRNA splicing. 88 The usefulness of phosphorodiamidate morpho lino oligomers coupled to argininerich cell-penetrating peptides has been repeatedly demonstrated against bacterial pathogens 89 and could be a viable option for any microbial gene of interest.
Specifi c antibody therapy
Specifi c biological therapy for infectious pathogens targets not only drug-resistant pathogens but also their immune evasion mechanisms. 90 An antibody directed against CD19 (a B-cell marker) fused to a T-cell signalling molecule can be expressed in T cells and could kill target cells once they encounter their nominal target antigen. Such CD19 chimeric-antigen-receptor cells are used to remove Epstein-Barr-virus-positive lymphoma cells in the case of post-transplantation proliferative diseases. 91 Similar approaches can be used for the eff ective removal of pathogen-infected cells when very specifi c antibodies exist and if target molecules are expressed on infected cells only. 92
Antibiotic-resistant bacterial respiratory tract infections
The frequency and spectrum of resistance to antibiotics in specifi c bacterial pathogens that cause respiratory tract infections continues to increase worryingly. Multidrugresistant Streptococcus pneumoniae-with resistance to three or more antibiotics-was initially noted in 1977 in South Africa 93 and subsequently in many other countries, with alarming rates of 30-50% of S pneumoniae that are multidrug resistant in the USA and Spain. [94] [95] [96] The European Antimicrobial Resistance Surveillance System showed that 22·2% of S pneumoniae were intermediate penicillin susceptible, 10·9% were penicillin resistant, and 21·1% were resistant to erythromycin. 97 Concerns about multidrug-resistant and pan-antibioticresistant Gram-negative bacteria 98, 99 are focused on Klebsiella pneumoniae, Enterobacter spp (production of extended spectrum β lactamase, Klebsiella pneumoniae carba penemase, NDM1, and AmpC), Acinetobacter baumannii, and Pseudomonas aeruginosa. In one survey of US health centres, 78% of Gram-negative bacteria were resistant to all antibiotics except colistin (to which 62% of Acinetobacter spp, 59% of Pseudomonas spp, and 52% of Enterobacter spp were resistant). 98 Therapeutic options to treat these infections are limited. 100, 101 Carbapenems are recommended for organisms that produce extended-spectrum β lactamases. 101 In a metaanalysis, [102] [103] [104] [105] [106] doripenem was more eff ective for P aeruginosa infections than were comparators in a modifi ed intention-to-treat analyses. Polymyxin B and colistin are concentration-dependent bactericidal agents that bind to bacterial cell membranes and have reliable activity against Acinetobacter spp. Novel β-lactamase inhibitors 107 and antibiotic com bination therapies 108 might provide stopgap measures for fulfi lling clinical need. Antibiotic development pipelines remain thin, 109, 110 and global attention is focused on increasing awareness for investments into the development of new antibacterial agents 111 and other antibacterial innovations, coupled to raising global awareness for more prudent use of available drugs. 112
Multidrug-resistant pulmonary tuberculosis Incidence
In 2012, an estimated 1·3 million people died worldwide from tuberculosis, 170 000 of whom had multidrugresistant disease. 113 Multidrug-resistant tuberculosis, which is caused by Mycobacterium tuberculosis bacilli resistant to at least isoniazid and rifampicin, is now widespread globally, with an estimated half a million cases in 2012. 2 Extensively drug-resistant tuberculosisresistance to rifampicin, isoniazid, any fl uoroquinolone, and at least one of the three injectable second-line drugs, amikacin, kanamycin, and capreomycin-has been reported in 92 countries. 113 WHO recommends use of second-line drugs for 18-24 months or longer for extensively drug-resistant or multidrug-resistant disease. 114, 115 Treatment success rates are low in both individualised and standard regimens and new drugs and regimens are needed.
New drugs pipeline
In the past 5 years, a promising pipeline of new drugs for the treatment of multidrug-resistant and extensively drug-resistant tuberculosis has emerged. 115 Progress has been made by repurposing drugs that are already available, including re-engineering existing antibacterial compounds and redesigning scaff olds, leading to discovery of new compounds. 116, 117 Two new drugs, delamanid (OPC-67683) and bedaquiline (TMC207 or R207910), have been approved by regulatory authorities. These new drugs are combined with older drugs to treat multidrug-resistant disease. 118, 119 
Host-directed adjunct therapies
Several approaches to rational development of adjunct immune-based therapies for multidrug-resistant tuberculosis have been developed. 120, 121 Non-steroidal antiinfl ammatory drugs can reduce M tuberculosis load and Series alleviate lung disease 122 in mice. 123 Effl ux pump inhibitors such as verapamil and reserpine reduce macrophageinduced drug tolerance, and thus could be used as adjunct host-directed therapies. 124, 125 Phosphodiesterase inhibitors such as cilostazol and sildenafi l improve mycobacterial clearance and decrease time to sterilisation by reducing tissue infl ammation. 126 A range of adjunct immunotherapy approaches implicating cytokines or their inhibitors and other biological immunomodulatory compounds are being assessed as means to limit damage from infl ammatory responses against M tuberculosis. Various cytokine regimens, including interferon c or interleukin 2, have been assessed, with variable eff ect. 127, 128 The antiinfl ammatory eff ects of macrolide antibiotics need to be further studied. 129 Whole genome sequencing might allow for rapid determination of resistance patterns of M tuberculosis strains, enabling tailored treatment regimens. Other immunomodulatory strategies include restoration of eff ective antipathogen-directed immunoresponses-and consequent decreasing of damaging host responses in lung tissues-in multidrug-resistant tuberculosis with infusions of the patient's own bonemarrow-derived stromal cells. A phase 1 trial showed that the procedure is safe, 130 and phase 2 trials are planned to assess the eff ects of mesenchymal stromal cell adjunct therapy on clinical and microbiological outcomes.
Fungal respiratory tract infections Frequency
Invasive fungal respiratory tract infections are increasingly reported worldwide (table 3) . 131, 132 The two most common pulmonary fungal pathogens are Aspergillus fumigatus and Pneumocystis jirovecii. They increasingly represent primary causes of morbidity and mortality in critically ill patients across Europe, Africa, and Asia as a result of more people living with HIV, increased use of immunomodulatory drugs in patients with cancer, transplantations, and use of broad-spectrum antibiotics. Some patients with relapsed or micro biologically unconfi rmed multidrug-resistant tuber culosis have alternative diagnoses, including chronic pulmonary aspergillosis, and more com prehensive searches for alternative fungal diagnoses in smear and culture negative cases should be done in patients with multidrug-resistant disease. 133
Invasive pulmonary aspergillosis
Aspergillus is the most important fungal cause of invasive pulmonary disease, and A fumigatus is the cause in more than 75% of cases. Voriconazole is the most eff ective treatment for invasive aspergillosis but resistance has been noted on all continents except South America. 134, 135 Widespread use of the azoles as fungicides in agriculture has led to the environmental development of pan-azole resistance. 136 Resistance can also emerge during treatment, typically to itraconazole, and is possibly linked to a combination of low blood concentrations of the drug and high fungal loads. [137] [138] [139] Modelling suggests that more than 6·5 million people have severe asthma with fungal sensitisations, as much as 50% of adults with asthma who attend secondary care have fungal sensitisation, and an estimated 4·8 million adults have allergic bronchopulmonary aspergillosis. 140, 141 People with asthma who are sensitised to A fumigatus have a much higher rate of bronchiectasis than do those who are unsensitised. Reclassifi cation of aspergillosis in adults with cystic fi brosis by aspergillus serology (IgE and IgG) and both PCR and antigen on sputum showed three distinct classes of aspergillosis. 18% had allergic bronchopulmonary disease, 15% had aspergillus sensitisation, and 30% had aspergillus bronchitis; the remaining patients had no disease. Long-term oral antifungal therapy is benefi cial for 60-80% of patients with asthma, but is of unproven benefi t in cystic fi brosis. 142 Resistance in A fumigatus has been reported throughout Europe in roughly 4% of samples from patients with cystic fi brosis. 143, 144 
Disseminated Emmonsia spp infections
A new fungus causing disseminated infections in patients with AIDS was identifi ed in 2009. 145 Molecular identifi cation on the basis of ITS1 and ITS2 sequencing showed that all isolates of this new species were tightly clustered and were most similar to Emmonsia pasteuriana and Emmonsia parva, and slightly more distantly related to Histoplasma capsulatum. Clinical features of infection included fever, loss of weight, anaemia, skin lesions akin to those in disseminated histoplasmosis, and a chest radiograph similar to that noted in pulmonary tuberculosis. The fungus was cultured from skin and blood, but not sputum or CSF. Signifi cant clinical responses were noted when patients were given intravenous amphotericin B followed by itraconazole. 145 
Advances in antifungal therapy
A large combination study 146 Series did not reach its primary endpoint of reduced mortality, although patients with positive galactomannan seemed to benefi t most. Guidelines for management of invasive aspergillosis still favour voriconazole over all other treatments and combination therapy is not usually recommended. A tablet formulation of posaconazole, which is more bioavailable than the oral suspension, is available and can be given once a day, 147 and the US Food and Drug Administration has approved an intravenous suspension of the drug. The only new drug to be approved is isavuconazole, a broad-spectrum azole, which will be available in intravenous and oral forms (application for approval was submitted in July, 2014). Itraconazole seems safe in the fi rst trimester of pregnancy, whereas fl uconazole increases the risk of Fallot's tetralogy by a factor of three to one in 1000. 148 Drivers for the development of new antifungal drugs include inadequate response rates, the absence of oral preparations of echinocandins, drug interactions, important drug toxic eff ects (especially amphotericin B and voriconazole), and triazole and echinocandin resistance. Several drugs are being repurposed for use as antifungals, and new drugs are under development (table 4) . [149] [150] [151] [152] [153] [154] [155] Sertraline, which is used for depression, has synergistic activity with fl uconazole in a murine model of cryptococcal infection. 156 Calcineurin and targets of rapamycin inhibitors have antifungal activity, which is synergsitic with that of azoles. 157 Hsp90 inhibitors initially developed for cancer treatment can improve fl uconazole activity in vitro and in animals. 158 Enoxacin, a fl uoroquinolone antibiotic, shows activity in a murine candidiasis model. 159
Host-directed therapy
Although azoles are important for the treatment of invasive pulmonary aspergillosis, the degree of immunosuppression and other immunological factors have a role in treatment outcomes. Antifungal immune responses could be improved by adaptive transfer of pathogen-specifi c T cells directed against invasive and pulmonary fungal infections, particularly infections with candida, aspergillus, and mucormycetes, especially after allogeneic stem-cell transplantation. T-cell responses are MHC class I restricted (for CD8positive T cells) or MHC class II restricted (for CD4positive T cells), and thus an eff ective T-cell response needs to match the genetic background of the patient. T-cell transfer was developed on the basis of the promising fi nding that transfer of pathogen-specifi c T-cell clones induces clinically signifi cant responses. 160, 161 Several approaches have been used to obtain these pathogen-specifi c T cells. Anti-pathogenspecifi c T cells can be expanded ex vivo under appropriate conditions (usually with the help of recombinant cytokines, synthetic peptides, or cellular components representing the pathogen). Responder T cells are identifi ed by interferon-γ production, removed via an interferon-capture assay, and transferred into the patient. This approach requires time for expansion of T cells (either the patient's own or those of an MHC-matched donor). This protocol enabled the expansion of Aspergillus spp, Candida spp, with the terms "respiratory tract", "pneumonia", "infections", "bacteria", "virus", "fungus", and "mycobacteria". We also combined these terms with the words "antibiotic", "antibiotic resistance", "treatment", "drugs", "drug development", "drug pipeline", "antibiotic development", "host-directed", "therapy", "adjunct therapy", "steroids", and "immunotherapy". We complemented the search with publications from WHO, the US Centers for Disease Control and Prevention, http://clinicaltrials. gov, and Google Scholar. We also reviewed studies cited by articles identifi ed by this search.
and Mucor spp-reactive T cells defi ned by interferon-γ production. Upon re-encounter with the nominal target antigen, the T cells proliferated and increased the antifungal reactivity of phagocytes. 162
Conclusion
New and antimicrobial-resistant species of bacteria, viruses, and fungi continue to emerge because of the remarkable genetic and adaptable plasticity of the microbiota. 163 Respiratory tract infections are among the top two causes of death globally. 164, 165 Microorganisms do not respect international boundaries, and ease of travel and airborne spread make them a threat to global health security. The increasing frequency of antibiotic resistance and limited therapeutic options emphasise the urgent need for more international cooperation to tackle new emerging microbial threats and multidrug-resistant microbes. Development of new therapeutic options needs to be coupled to international regulations on the use and prescription of antimicrobial drugs.
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